Simcere Pharmaceutical Enhances Portfolio with New Cancer Drug

Simcere Pharmaceutical Group Limited (HK:2096) has released an update.

Simcere Pharmaceutical Group Limited has announced the signing of an exclusive agreement with TargetRx to commercialize a new non-small cell lung cancer drug, TGRX-326, in mainland China. The deal includes an initial payment of over $20 million to TargetRx, which will also receive compensation for promotional services. TGRX-326, a promising treatment for ALK/ROS1 positive fusion gene-driven cancer, has shown notable efficacy and safety in early trials and has the potential to treat brain metastases due to its high blood-brain barrier permeability.

For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.